In addition, even if estrogen levels were not measured because our study is focused on TNBC, we may not exclude that dysregulated levels of the former could impact tumor metabolism in other subtypes of breast cancer as estrogen is also a known activator of the PI3K-AKT signaling pathway [21]. This evidence concerns the gene AKT1 and breast cancer.